The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Rybrila 160 micrograms/ml Oral Solution

Clinigen Healthcare B.V.PA22701/001/001

Main Information

Trade NameRybrila 160 micrograms/ml Oral Solution
Active SubstancesGlycopyrronium bromide
Dosage FormOral solution
Licence HolderClinigen Healthcare B.V.
Licence NumberPA22701/001/001

Group Information

ATC CodeA03AB02 glycopyrronium bromide


License statusAuthorised
Licence Issued23/07/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). Rybrila should be prescribed by physicians experienced in the treatment of paediatric patients with neurological disorders.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - HCP

Educational Materials - Patient

« Back